- Home
- GROY vs DCTH Comparison
GROY vs DCTH Comparison
Compare GROY & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROY | DCTH |
|---|---|---|
| Founded | 2020 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 702.0M | 578.4M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GROY | DCTH |
|---|---|---|
| Price | $2.62 | $14.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $5.03 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 1.1M | 264.6K |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $111.19 | $24.61 |
| Revenue Next Year | $20.28 | $24.27 |
| P/E Ratio | ★ N/A | $364.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.45 | $8.12 |
| 52 Week High | $5.45 | $17.42 |
Technical Indicators
Market Signals| Indicator | GROY | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 33.64 | 37.14 |
| Support Level | $2.45 | $11.43 |
| Resistance Level | $2.72 | $16.51 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 0.00 | 1.12 |
Price Performance
Historical ComparisonAbout GROY Gold Royalty Corp.
Gold Royalty Corp is principally engaged in acquiring gold-focused royalties, streaming, and similar interests. It is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. The Company operates in Bosnia and Herzegovina, Canada, which generates maximum revenue, the USA, Brazil, and Mexico.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.